O'Connell M J
J Clin Oncol. 1985 Jul;3(7):1032-9. doi: 10.1200/JCO.1985.3.7.1032.
There is currently no effective systemic therapy for advanced pancreatic cancer. No definitive controlled data exist that demonstrate a survival benefit for any particular regimen yet developed. A statistically significant short-term survival benefit has been seen in three consecutive GITSG trials using the FAMe regimen in patients with advanced gastric cancer. Occasional long-term responders have been seen with a variety of regimens, but there is no evidence of improved long-term (more than two years) disease-free survival with any regimen reported to date. Continuing research with emphasis on new drug development, innovative alterations in chemotherapy combinations and administration schedules, or entirely new treatment strategies, are clearly required to allow the clinical investigator and the clinical practitioner to achieve their common goal--improved long-term survival for patients with advanced pancreatic and gastric cancer.
目前，对于晚期胰腺癌尚无有效的全身治疗方法。尚无确凿的对照数据表明，已研发的任何特定方案能带来生存获益。在三项连续的胃肠道肿瘤研究组（GITSG）试验中，使用FAMe方案治疗晚期胃癌患者，观察到了具有统计学意义的短期生存获益。使用各种方案都曾出现过偶尔的长期缓解者，但迄今为止，尚无证据表明任何方案能改善长期（超过两年）无病生存率。显然需要继续开展研究，重点是新药研发、化疗联合方案及给药方案的创新性改变，或全新的治疗策略，以使临床研究者和临床从业者能够实现他们的共同目标——提高晚期胰腺癌和胃癌患者的长期生存率。
